Literature DB >> 16476510

Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.

Vinita Tripathi1, K T Chitralekha, Anand R Bakshi, Deepak Tomar, R A Deshmukh, M A Baig, D N Rao.   

Abstract

Plague is a zoonotic disease caused by Yersinia pestis, an etiological agent of pneumonic and bubonic plague. There is a need for an improved plague vaccine that may overcome the limitation of presently available whole cell vaccine. An alternative approach described here, is the use of protective epitopes from immunodominant antigen of Y. pestis. One such antigen is the F1 antigen, a major envelope and virulent protein that possess antiphagocytic and anti-microbial properties. The present study was aimed to develop a peptide-based vaccine, based upon the constructs made between B and T cell epitopes of F1 antigen of Y. pestis. The immunogenicity, IgG subclass pattern, affinity, avidity and in vivo protective efficacy of the antibodies generated for different B-T constructs were studied in murine model using microsphere as the delivery vehicle. The mode of immunization was both intranasal and intramuscular, with single and multiple doses of immunization, respectively. Intranasal immunization generated consistent high titre and long lasting immune response both for IgG and IgA in sera and sIgA in washes while intramuscular route generated peak IgG levels in sera only. The IgG isotypic levels pattern showed higher IgG2a/IgG2b levels in intranasal route while mixed isotypic levels of IgG1, IgG2a/IgG2b were observed in intramuscular route. The affinity and relative avidity of antibodies showed best results with intranasal route as compared to the intramuscular route. The specific activity measurement (IgG/IgA content) in sera and washes were well correlated with the antibody levels. Finally, in vivo protective studies showed that B1T1 and B2T1 conjugates protected the mice till day 15 while rest of the conjugates showed poor protection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476510     DOI: 10.1016/j.vaccine.2006.01.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

Authors:  Jeremy L Goodin; David F Nellis; Bradford S Powell; Vinay V Vyas; Jeffrey T Enama; Lena C Wang; Patrick K Clark; Steven L Giardina; Jeffery J Adamovicz; Dennis F Michiel
Journal:  Protein Expr Purif       Date:  2006-12-31       Impact factor: 1.650

2.  Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.

Authors:  Jayaprakash Babu Uppada; Arif Azam Khan; Ajaz Ahmad Bhat; Ranjana Deshmukh; Donthamsetty Nageswara Rao
Journal:  Med Microbiol Immunol       Date:  2009-09-25       Impact factor: 3.402

3.  Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1.

Authors:  Teena Mohan; D Mitra; D N Rao
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

Review 4.  The route less taken: pulmonary models of enteric Gram-negative infection.

Authors:  Michael L Fisher; Wei Sun; Roy Curtiss
Journal:  Pathog Dis       Date:  2013-11-21       Impact factor: 3.166

5.  Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost.

Authors:  Karina Ramirez; Alejandra V E Capozzo; Scott A Lloyd; Marcelo B Sztein; James P Nataro; Marcela F Pasetti
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

Review 6.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

7.  Yersinia pestis Antigen F1 but Not LcrV Induced Humoral and Cellular Immune Responses in Humans Immunized with Live Plague Vaccine-Comparison of Immunoinformatic and Immunological Approaches.

Authors:  Valentina A Feodorova; Anna M Lyapina; Maria A Khizhnyakova; Sergey S Zaitsev; Yury V Saltykov; Vladimir L Motin
Journal:  Vaccines (Basel)       Date:  2020-11-19

8.  On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity.

Authors:  Salvador Eugenio C Caoili
Journal:  Adv Bioinformatics       Date:  2012-11-14

Review 9.  Contagious bovine pleuropneumonia: a rationale for the development of a mucosal sub-unit vaccine.

Authors:  Laurence Dedieu-Engelmann
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2007-08-16       Impact factor: 2.268

10.  Construction of a Live-Attenuated Vaccine Strain of Yersinia pestis EV76-B-SHUΔpla and Evaluation of Its Protection Efficacy in a Mouse Model by Aerosolized Intratracheal Inoculation.

Authors:  Junxia Feng; Yingying Deng; Mengjiao Fu; Xueyuan Hu; Wenbo Luo; Zhiyu Lu; Lupeng Dai; Huiying Yang; Xiaodong Zhao; Zongmin Du; Bohai Wen; Lingxiao Jiang; Dongsheng Zhou; Jun Jiao; Xiaolu Xiong
Journal:  Front Cell Infect Microbiol       Date:  2020-09-08       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.